2.61

2.97% -0.08

Larimar Therapeutics Inc (LRMR)

Overview News Price History Option Chain Financials Discussions Forecast

Larimar Therapeutics Inc stock is traded at $2.61, with a volume of 506.87K. It is down -2.97% in the last 24 hours and down -20.18% over the past month. Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Previous Close:

$2.69

Open:

$2.71

24h Volume:

506.87K

Relative Volume:

0.70

Market Cap:

$166.54M

Revenue:

Net Income/Loss:

$-36.95M

P/E Ratio:

-3.1071

EPS:

-0.84

Net Cash Flow:

$-33.46M

1W Performance:

-14.71%

1M Performance:

-20.18%

6M Performance:

-63.75%

1Y Performance:

-71.94%

1-Day Range:

$2.5417

$2.79

1-Week Range:

$2.5417

$3.19

52-Week Range:

$2.5417

$11.20

Larimar Therapeutics Inc Stock (LRMR) Company Profile

Name

Larimar Therapeutics Inc

Sector

Healthcare (1169)

Industry

Biotechnology (679)

Phone

844-511-9056

Address

THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA

Employee

Twitter

Next Earnings Date

2025-03-14

Latest SEC Filings

LRMR's Discussions on Twitter

Compare LRMR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LRMR Larimar Therapeutics Inc	2.61	166.54M	0	-36.95M	-33.46M	-0.84
VRTX Vertex Pharmaceuticals Inc	502.92	129.14B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	680.61	74.41B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	581.21	35.31B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	241.75	31.30B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	254.57	27.35B	3.32B	-860.46M	-1.04B	-8.32

Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-29-25	Initiated	Truist	Buy
Oct-16-24	Initiated	Oppenheimer	Outperform
Oct-03-24	Initiated	Wedbush	Outperform
Oct-02-24	Initiated	H.C. Wainwright	Buy
Sep-04-24	Initiated	Robert W. Baird	Outperform
Apr-03-24	Initiated	Leerink Partners	Outperform
Nov-17-23	Upgrade	Citigroup	Neutral → Buy
Oct-19-22	Initiated	Guggenheim	Buy
Feb-15-22	Downgrade	William Blair	Outperform → Mkt Perform
Feb-10-21	Initiated	JMP Securities	Mkt Outperform
Feb-01-21	Initiated	William Blair	Outperform

View All

Larimar Therapeutics Inc Stock (LRMR) Latest News

Mar 08, 2025

Larimar Therapeutics to Present at Leerink Partners Global Healthcare Conference - MSN

Mar 08, 2025

Mar 03, 2025

Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference - GlobeNewswire

Mar 03, 2025

Will Larimar's Rare Disease Pipeline Updates Move the Needle? Key Investor Conference Coming - StockTitan

Mar 03, 2025

Feb 26, 2025

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World

Feb 26, 2025

Feb 25, 2025

Financial Metrics Exploration: Understanding Larimar Therapeutics Inc (LRMR) Through Ratios - The Dwinnex

Feb 25, 2025

Feb 14, 2025

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Holdings Boosted by SG Americas Securities LLC - Defense World

Feb 14, 2025

Feb 12, 2025

Insiders Re-Evaluate Their US$522.0k Stock Purchase As Larimar Therapeutics Falls To US$215m - Simply Wall St

Feb 12, 2025

Feb 05, 2025

BlackRock, Inc. Increases Stake in Larimar Therapeutics Inc - GuruFocus.com

Feb 05, 2025

Insider’s View: Deciphering Larimar Therapeutics Inc (LRMR)’s Financial Health Through Ratios - The Dwinnex

Feb 05, 2025